# EDGAR Filing Document

**Accession Number:** 0002010788
**File Stem:** 0001140361-25-023395
**Filing Date:** 2025-6
**Character Count:** 2985
**Document Hash:** bed94446c6581527b64649c500518728
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-023395.hdr.sgml**: 20250623

**ACCESSION NUMBER**: 0001140361-25-023395

**CONFORMED SUBMISSION TYPE**: DEFR14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20250623

**DATE AS OF CHANGE**: 20250623

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EXOZYMES INC.
- **CENTRAL INDEX KEY:** 0002010788
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 834550057
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFR14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42204
- **FILM NUMBER:** 251066016

**BUSINESS ADDRESS:**
- **STREET 1:** 750 ROYAL OAKS DR
- **CITY:** MONROVIA
- **STATE:** CA
- **ZIP:** 91016
- **BUSINESS PHONE:** (626) - 415 - 1488

**MAIL ADDRESS:**
- **STREET 1:** 750 ROYAL OAKS DR
- **CITY:** MONROVIA
- **STATE:** CA
- **ZIP:** 91016

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Invizyne Technologies Inc
- **DATE OF NAME CHANGE:** 20240205

### UNITED STATES<br>

### SECURITIES AND EXCHANGE COMMISSION<br>

#### Washington, D.C. 20549

### Amendment No. 1 to<br>

### SCHEDULE 14A<br>

#### PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE <br>

#### SECURITIES EXCHANGE ACT OF 1934
Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐<br> Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☒<br> Definitive Proxy Statement

☐<br> Definitive Additional Materials

☐<br> Soliciting Material Pursuant to §240.14a-11(c) or §240.14a-2

## EXOZYMES INC. <br>

#### (Exact name of registrant as specified in its charter)
Payment of Filing Fee (Check the appropriate box):

☒<br> No fee required.

☐<br> Fee paid previously with preliminary materials.

☐<br> Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

------

#### EXPLANATION OF FILING
This filing is being made to correct the proxy card that was filed on June 20, 2025 by ExoZymes Inc. The change is to correct the voting for director nominees.

The proposal number 1 originally did not provide for the ability of a shareholder to withhold for all or for one or more of the director nominees. The card has been adjusted to provide for the ability of the shareholder to select either a vote "For All," "Withhold All" or "For All Except" and an explanation as to how to withhold authority for a specific director nominee for those shareholders selecting to vote "For All Except."

As the proxy materials have not yet been distributed as of the date of this filing, shareholders will only be receiving the corrected proxy card; therefore there is not being provided to shareholders differently colored or otherwise separately distinguishable proxy cards.

------

![](ny20050076x2_pc1.jpg)<br>

------

![](ny20050076x2_pc2.jpg)<br>